Tirzepatide vs semaglutide: A head-to-head comparison for management of obesity

A/Prof Samantha Hocking

writer

A/Prof Samantha Hocking

Endocrinologist; Royal Prince Alfred Hospital; Clinical Academic at Charles Perkins Research Centre, University of Sydney; President, National Association of Clinical Obesity Services (NACOS)

Claim CPD for this activity

Educational Activities (EA)

0.5 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0.5 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

1 hours

These are activities that use your work data to ensure quality results.

EA
0.5 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0.5 minutes

These are activities that require reflection on feedback about your work.

MO
1 minutes

These are activities that use your work data to ensure quality results.

The SURMOUNT-5 trial has provided definitive evidence that tirzepatide is superior to semaglutide for obesity treatment, achieving an additional 6.5% body weight reduction and nearly doubling the proportion of patients who lose 25% or more of their body weight.

This landmark head-to-head comparison, recently presented at the European Congress of Obesity in Spain, represents the first direct evidence comparing these two leading obesity medications helping to guide optimal treatment selection.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

References

N Engl J Med 2021;384:989-1002 (STEP 1)
N Engl J Med 2022;387:205-216 (SURMOUNT-1)
N Engl J Med 2025;393:26-36 (SURMOUNT-5)

Further your CPD learning

Based on this educational activity, complete these learning modules to gain additional CPD.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Deborah Bateson AM

Prof Deborah Bateson AM

The Natural Estrogen Debate: A Focus on Combined Oral Contraception

Prof Genie Pedagogos, Prof Richard MacIsaac & A/Prof Ralph Audehm

Prof Genie Pedagogos, Prof Richard MacIsaac & A/Prof Ralph Audehm

Panel Discussion on GLP1s for Chronic Kidney Disease in Type 2 Diabetes

Dr Gabby Mahoney

Dr Gabby Mahoney

Eczema Management Practical Tips

Prof Rodney Baber AM

Prof Rodney Baber AM

Menopausal Hormone Therapy and its Cardiovascular Benefits

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

A/Prof Samantha Hocking

writer

A/Prof Samantha Hocking

Endocrinologist; Royal Prince Alfred Hospital; Clinical Academic at Charles Perkins Research Centre, University of Sydney; President, National Association of Clinical Obesity Services (NACOS)

Test your knowledge

Recent articles

Latest GP poll

In your perception, how has Donald Trump's election to the US and related political discourse in the media concerning vaccine safety impact on your patients' willingness to follow Australian government recommended vaccinations?

Very negative impact

0%

Somewhat negative impact

0%

No noticeable impact

0%

Somewhat positive impact

0%

Very positive impact

0%

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Upcoming Healthed Webcast

MHT and its cardiovascular benefits

Tuesday 28th October, 7pm - 9pm AEDT

Speaker

Prof Rodney Baber AM

Obstetrician and Gynaecologist; Clinical Professor, Obstetrics and Gynaecology, The University of Sydney

We invite you to our next free webcast, where Prof Rod Baber will present on menopausal hormone therapy. Up to 4 hours CPD. RACGP & ACRRM accredited.